Colony-Stimulating Factors (Hemopoietic Colonies/Autoradiography/Clonal Cultures/Clone Transfer) D

Total Page:16

File Type:pdf, Size:1020Kb

Colony-Stimulating Factors (Hemopoietic Colonies/Autoradiography/Clonal Cultures/Clone Transfer) D Proc. Natl. Acad. Sci. USA Vol. 88, pp. 6239-6243, July 1991 Medical Sciences Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: Effects of combination with colony-stimulating factors (hemopoietic colonies/autoradiography/clonal cultures/clone transfer) D. METCALF* AND N. A. NICOLA The Walter and Eliza Hall Institute of Medical Research, P.O. Royal Melbourne Hospital 3050, Victoria, Australia Contributed by D. Metcalf, April 16, 1991 ABSTRACT Stem cell factor (SCF), the ligand for the c-kit for up to 7 days in a fully humidified atmosphere of 10%o CO2 protooncogene product, was able to stimulate blast cell and in air. The transfer ofintact clones to recipient cultures or the granulocytic colony formation by precursors from normal reculture of resuspended colony cells was performed as murine bone marrow. The blast cell colonies contained a high described (6). Colony formation was scored by using a content of progenitor cells able to form macrophage and/or dissection microscope at 35x magnifications, and cultures granulocyte colonies. Clone transfer studies, the secondary were then fixed by using 1 ml of 2.5% glutaraldehyde. The culture of colony cells, and the culture of populations freed of intact cultures were floated onto slides and, after drying, accessory cells all indicated a direct proliferative action ofSCF. were stained for acetylcholinesterase and then stained with SCF receptors were present in high numbers on blast cells and Luxol fast blue and hematoxylin. in lower numbers on immature granulocytic, monocytic, and Stimuli. All stimuli used were recombinant nonglycosy- eosinophilic cells. Combination ofSCF with granulocyte, gran- lated factors purified after expression in Escherichia coli: ulocyte-macrophage, or multipotential colony-stimulating fac- SCF (rat) and granulocyte colony-stimulating factor (G-CSF; tors, but not macrophage colony-stimulating factor, resulted in human 108 units/mg) respectively supplied by K. Zsebo and enhancement of colony size. Granulocyte colony-stimulating L. Souza (Amgen Biologicals); and recombinant murine factor enhanced cell proliferation initiated by SCF, but not granulocyte-macrophage colony-stimulating factor (GM- vice-versa, and resulted in a 10-fold increase in colony cell CSF), macrophage colony-stimulating factor (M-CSF), and numbers and a 7-fold increase in progenitor cells in blast multipotential colony-stimulating factor (Multi-CSF) pro- colonies. No evidence was obtained that SCF, alone or in duced in this laboratory. After purification, the latter group combination with granulocyte colony-stimulating factor, could of CSFs assayed at 3 x 108, 1 x 108, and 1 x 108 units/mg stimulate self-generation by blast colony-forming cells. of protein, respectively, by the methods for unit estimation described (6). The protooncogene c-kit encodes a membrane receptor, Stem Cell Enrichment. Enrichment by fluorescence- present on hemopoietic and other cells but defective or activated cell sorting (FACS) of stem and progenitor cells absent in the various W (dominant spotting) mutant mice with from normal mouse bone marrow was based on methods defective stem cells and erythropoiesis (1, 2). The ligand for described previously (7). the c-kit product has recently been purified and cloned (3, 4), Autoradiographic Studies. Recombinant rat SCF was ra- and production ofthis molecule is absent or defective in mice diolabeled with 1251 (125I-SCF) by using iodine monochloride with the Steel mutation that also exhibit defective erythro- (8) to a specific radioactivity of 30,000 cpm/ng. BALB/c poiesis. Initial studies documented the ability of the c-kit bone marrow cells (5 x 106) were incubated with 125I-SCF ligand [termed stem cell factor (SCF) or mast cell growth (200,000 cpm) for 45 min at 230C in 60 1.l of RPMI 1640 factor] to stimulate the proliferation of mast cells (3, 4) and medium containing 10%o fetal calf serum and 10 mM Hepes primitive hemopoietic precursor cells (3) and to enhance buffer (pH 7.3). Specificity was determined in parallel tubes erythropoietin-stimulated erythropoiesis and granulocyte- containing 300 ng of unlabeled SCF (3400 + 100 cpm versus macrophage colony formation in the presence of colony- 350 + 40 cpm). Cytocentrifuge cell preparations were fixed stimulating factors (4, 5). with 2.5% glutaraldehyde and then exposed for 21 days with The present studies were undertaken to establish whether Kodak NTB2 emulsion. After development, the preparations or not SCF is a direct proliferative stimulus for hemopoietic were stained with May-Grunewald Giemsa. cells and the nature of the enhanced cell proliferation ob- servable when SCF is used in combination with the various RESULTS colony-stimulating factors. SCF, acting alone in cultures of 75,000 bone marrow cells, stimulated colony formation, but the concentration required MATERIALS AND METHODS was 1000-fold higher than for the colony-stimulating factors Cultures. Primary cultures were performed in 35-mm Petri (Fig. 1). The maximum number of colonies developing was dishes usually containing 75,000 bone marrow cells from only two-thirds of that stimulated by GM-CSF but twice the 8-week-old C57BL/6/WEHI mice in a 1-ml volume of Dul- number stimulated by G-CSF. After 7 days of culture, becco's modified Eagle's medium with a final concentration SCF-stimulated colonies had a distinctive morphology. The of 20% (vol/vol) fetal calf serum and 0.3% agar (6). Stimuli in a volume of 0.1 ml were added prior to the addition of the Abbreviations: SCF, stem cell factor; CSF, colony-stimulating fac- cells in agar-medium. After gelling, cultures were incubated tor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, gran- ulocyte-macrophage colony-stimulating factor; M-CSF, macro- phage colony-stimulating factor; Multi-CSF, multipotential colony- The publication costs of this article were defrayed in part by page charge stimulating factor; IL-4, IL-5, and IL-6, interleukins 4, 5, and 6; payment. This article must therefore be hereby marked "advertisement" FACS, fluorescence-activated cell sorting. in accordance with 18 U.S.C. §1734 solely to indicate this fact. *To whom reprint requests should be addressed. 6239 Downloaded by guest on September 28, 2021 6240 Medical Sciences: Metcalf and Nicola Proc. Natl. Acad. Sci. USA 88 (1991) 800 > 600 80 - /C~~GSF ~~~~~~~~SCF k 400 40 200 40 0.015 0.25 4 62 1000 Concentration ng/rrd 400 -~~~~~ I FIG. 1. Stimulation of colony formation by SCF, G-CSF, or . GM-CSF in cultures of 75,000 C57BL/6/WEHI bone marrow cells. 200 _ p/G~S~F Cultures scored at day 7 ofincubation and data points represent mean / colony counts from replicate cultures. | | |oc colonies were small and of three major types-multicentric colonies containing blast cells, compact colonies usually 12.5 50 100 200 Cels per dish x 10-3 containing immature granulocytes, and colonies of mature granulocytic cells similar to those stimulated by G-CSF. The FIG. 2. Linearity of colony formation stimulated by SCF or cultures also contained a few small macrophage or granulo- G-CSF in cultures of varying numbers of C57BL/6/WEHI bone cyte-macrophage colonies but no eosinophil, megakaryo- marrow cells. Note the progressive increase in mean colony size with cytic, erythroid, or multipotential colonies (Table 1). increasing numbers of cultured cells. Mean data are from duplicate SCF-stimulated colony formation was linear with respect cultures and pools of 50 colonies (where possible). to cultured cell numbers (Fig. 2) but, as cultured cell numbers were increased, there was a progressive rise in mean colony with size enhancement increasing progressively with increas- cell numbers (up to 10-fold), a phenomenon seen also in ing SCF concentrations (Fig. 4). A similar result was ob- G-CSF-stimulated cultures. The increased colony size in- served with the reverse combination using increasing con- volved both blast cell and immature granulocytic colonies. centrations of G-CSF. No change occurred in the relative frequencies ofthe various Direct Prolfferative Actions of SCF. The linearity of colony colony types but, in cultures ofhigh cell numbers, a few small formation with cultured cell numbers suggested a direct megakaryocytic colonies were sometimes present. action of SCF, but further evidence for this was sought by In cultures containing 100 ng of SCF per ml combined with clone transfer studies and the culture ofFACS-enriched stem 1000 units of colony-stimulating factors per ml (a 4-fold and progenitor cells. supramaximal concentration), there were only additive or The subsequent proliferation of individual day 3 clones, subadditive effects on numbers. with total colony However, initiated by either SCF or G-CSF, was analyzed and then the G-CSF, GM-CSF, or Multi-CSF there was a marked super- clones were transferred to cell-free recipient cultures con- additive effect on colony size that was most evident with the combination ofSCF and G-CSF 3). In cultures with SCF taining no stimulus, SCF, or G-CSF. Clones transferred were (Fig. the 20 from each donor culture and excluded those and G-CSF, there was a >10-fold increase in mean colony largest cell numbers. The sizes of blast cell and immature granulo- already showing evidence of maturation from their dispersed cytic colonies were enhanced, but the cultures still contained small mature granulocytic colonies typical of those seen in cultures stimulated by either SCF or G-CSF alone. Differ- ential colony counts suggested that combination of the two stimuli resulted in conversion of some blast colonies to granulocyte-containing colonies (Table 1). Combination of G-CSF with increasing concentrations of SCF indicated a simple additive effect on colony numbers, Table 1. Colony formation stimulated by SCF alone or in combination with G-CSF Mean Number of colonies Mean cells per Stimulus per ml colonies colony Blast G GM M SCF, 100 ng 81 370 19 51 8 3 G-CSF, 2 ng 43 300 0 31 6 6 20 40 60 80 100 120 140 SCF, 100 ng + N wnbe of coloies G-CSF, 2 ng 121 2740 10 89 16 6 Cultures contained 75,000 C57BL/6/WEHI bone marrow cells FIG.
Recommended publications
  • The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models
    biomolecules Review The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models Meera Krishnan 1, Sahil Kumar 1, Luis Johnson Kangale 2,3 , Eric Ghigo 3,4 and Prasad Abnave 1,* 1 Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Gurgaon-Faridabad Ex-pressway, Faridabad 121001, India; [email protected] (M.K.); [email protected] (S.K.) 2 IRD, AP-HM, SSA, VITROME, Aix-Marseille University, 13385 Marseille, France; [email protected] 3 Institut Hospitalo Universitaire Méditerranée Infection, 13385 Marseille, France; [email protected] 4 TechnoJouvence, 13385 Marseille, France * Correspondence: [email protected] Abstract: Adult stem cells (ASCs) are the undifferentiated cells that possess self-renewal and differ- entiation abilities. They are present in all major organ systems of the body and are uniquely reserved there during development for tissue maintenance during homeostasis, injury, and infection. They do so by promptly modulating the dynamics of proliferation, differentiation, survival, and migration. Any imbalance in these processes may result in regeneration failure or developing cancer. Hence, the dynamics of these various behaviors of ASCs need to always be precisely controlled. Several genetic and epigenetic factors have been demonstrated to be involved in tightly regulating the proliferation, differentiation, and self-renewal of ASCs. Understanding these mechanisms is of great importance, given the role of stem cells in regenerative medicine. Investigations on various animal models have played a significant part in enriching our knowledge and giving In Vivo in-sight into such ASCs regulatory mechanisms. In this review, we have discussed the recent In Vivo studies demonstrating the role of various genetic factors in regulating dynamics of different ASCs viz.
    [Show full text]
  • Transforming Growth Factor-β in Stem Cells and Tissue Homeostasis
    Bone Research www.nature.com/boneres REVIEW ARTICLE OPEN Transforming growth factor-β in stem cells and tissue homeostasis Xin Xu1, Liwei Zheng2, Quan Yuan3, Gehua Zhen4, Janet L. Crane4,5, Xuedong Zhou1 and Xu Cao4 TGF-β 1–3 are unique multi-functional growth factors that are only expressed in mammals, and mainly secreted and stored as a latent complex in the extracellular matrix (ECM). The biological functions of TGF-β in adults can only be delivered after ligand activation, mostly in response to environmental perturbations. Although involved in multiple biological and pathological processes of the human body, the exact roles of TGF-β in maintaining stem cells and tissue homeostasis have not been well-documented until recent advances, which delineate their functions in a given context. Our recent findings, along with data reported by others, have clearly shown that temporal and spatial activation of TGF-β is involved in the recruitment of stem/progenitor cell participation in tissue regeneration/remodeling process, whereas sustained abnormalities in TGF-β ligand activation, regardless of genetic or environmental origin, will inevitably disrupt the normal physiology and lead to pathobiology of major diseases. Modulation of TGF- β signaling with different approaches has proven effective pre-clinically in the treatment of multiple pathologies such as sclerosis/ fibrosis, tumor metastasis, osteoarthritis, and immune disorders. Thus, further elucidation of the mechanisms by which TGF-β is activated in different tissues/organs and how targeted cells respond in a context-dependent way can likely be translated with clinical benefits in the management of a broad range of diseases with the involvement of TGF-β.
    [Show full text]
  • The Hepatocyte Growth Factor/Scatter Factor
    Cutting Edge: Identification of a Hybrid Cytokine Consisting of IL-7 and the β-Chain of the Hepatocyte Growth Factor/Scatter Factor This information is current as Laijun Lai and Irving Goldschneider of September 23, 2021. J Immunol 2001; 167:3550-3554; ; doi: 10.4049/jimmunol.167.7.3550 http://www.jimmunol.org/content/167/7/3550 Downloaded from References This article cites 30 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/7/3550.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 23, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. ● Cutting Edge: Identification of a Hybrid Cytokine Consisting of IL-7 and the ␤-Chain of the Hepatocyte Growth Factor/Scatter Factor1 Laijun Lai and Irving Goldschneider2 initiate or up-regulate the expression of terminal deoxynucleotidyl Pre-pro-B cell growth-stimulating factor (PPBSF) is a het- transferase, cytoplasmic Ig␮ heavy chain, and IL-7R␣-chain (Ref.
    [Show full text]
  • Caspase-Activated ROCK-1 Allows Erythroblast Terminal Maturation Independently of Cytokine-Induced Rho Signaling
    Cell Death and Differentiation (2011) 18, 678–689 & 2011 Macmillan Publishers Limited All rights reserved 1350-9047/11 www.nature.com/cdd Caspase-activated ROCK-1 allows erythroblast terminal maturation independently of cytokine-induced Rho signaling A-S Gabet1, S Coulon1, A Fricot1, J Vandekerckhove1, Y Chang2,3, J-A Ribeil1, L Lordier2,3, Y Zermati4, V Asnafi1, Z Belaid1, N Debili2,3, W Vainchenker2,3, B Varet1,5, O Hermine*,1,5 and G Courtois*,1 Stem cell factor (SCF) and erythropoietin are strictly required for preventing apoptosis and stimulating proliferation, allowing the differentiation of erythroid precursors from colony-forming unit-E to the polychromatophilic stage. In contrast, terminal maturation to generate reticulocytes occurs independently of cytokine signaling by a mechanism not fully understood. Terminal differentiation is characterized by a sequence of morphological changes including a progressive decrease in cell size, chromatin condensation in the nucleus and disappearance of organelles, which requires transient caspase activation. These events are followed by nucleus extrusion as a consequence of plasma membrane and cytoskeleton reorganization. Here, we show that in early step, SCF stimulates the Rho/ROCK pathway until the basophilic stage. Thereafter, ROCK-1 is activated independently of Rho signaling by caspase-3-mediated cleavage, allowing terminal maturation at least in part through phosphorylation of the light chain of myosin II. Therefore, in this differentiation system, final maturation occurs independently
    [Show full text]
  • Transmembrane Stem Cell Factor Protein Therapeutics Enhance Revascularization in Ischemia Without Mast Cell Activation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.06.028563; this version posted April 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Transmembrane Stem Cell Factor Protein Therapeutics Enhance Revascularization in Ischemia without Mast Cell Activation Eri Takematsu1, Jeff Auster1, Po-Chih Chen1, Sanjana Srinath1, Sophia Canga1, Aditya Singh1, Marjan Majid1, Michael Sherman2, Andrew Dunn1, Annette Graham3, Patricia Martin3 and Aaron B. Baker1,4,5,6 1Department of Biomedical Engineering, University of Texas at Austin, Austin, TX 2Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX 3Department of Biological and Biomedical Sciences, School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, Scotland, UK 4Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 5The Institute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX 6Institute for Biomaterials, Drug Delivery and Regenerative Medicine, University of Texas at Austin, Austin, TX Total Figures: 6 + 7 Supplemental Figures Total Tables: 1 Main Manuscript Word Count: 5,485 Running Title: Transmembrane SCF Nanodiscs Enhance Revascularization Correspondence to: Aaron B. Baker University of Texas at Austin Department of Biomedical Engineering 1 University Station BME 5.202D, C0800 Austin, TX 78712 Phone: 512-232-7114 E-mail: [email protected] Page 1 of 41 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.06.028563; this version posted April 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Mobilization Failure in Hematopoietic Stem Cell Transplantation
    MOBILIZATION FAILURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Siret Ratip Department of Haematology, Acıbadem University School of Medicine, İstanbuy, Turkey G-CSF–based mobilization regimens have a plantations, G-CSF is given at 10 μg/kg per day 5%-30% failure rate among healthy donors and subcutaneously with apheresis beginning on the patients, but the rate can be up to 60% in high- fifth day until the yield target is reached. There is risk patients such as those exposed to fludarabine. no evidence that twice daily administration gives a Poor mobilization has significant consequences for higher yield than once-daily (4). the patient with potential loss of the transplant as a treatment option. Repeated attempts at mobiliza- Combining G-CSF with chemotherapy for tion increase resource use, morbidity, and patient/ mobilization donor inconvenience. Therefore, there is much Combining G-CSF with chemotherapy achieves interest in the prevention and salvage of mobiliza- both mobilization and antitumor activity and has tion failure with novel strategies. been shown to result in a higher CD34+ cell yield than G-CSF alone (5). Regimens such as cyclo- The role of CD34+ cell dose in phosphamide, doxorubicin, vincristine, and pred- haematopoeitic stem cell transplantation nisone/dexamethasone, high-dose cytarabine, and Benefits of rapid recovery in HSCT are reduced cisplatin or cyclophosphamide 1-5 g/m2 have been hospitalization, blood product usage, and infec- used with G-CSF which is commenced 1-3 days tions. Minimum threshold of CD34+ cell dose for following cyclophosphamide. Apheresis is usually autologous transplantation is currently 2 × 106 started when leukocyte count reaches > 2 × 109/L.
    [Show full text]
  • Cytokine Receptors and Hematopoietic Differentiation
    Oncogene (2007) 26, 6715–6723 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Cytokine receptors and hematopoietic differentiation LRobb The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia Colony-stimulating factors and other cytokines signal via finely tuned regulatory pathways that control both basal their cognate receptors to regulate hematopoiesis. In and emergency hematopoiesis are mediated largely by many developmental systems, inductive signalling deter- cytokines and their cognate receptors. Cytokines are a mines cell fate and, by analogy with this, it has been large family of specific extracellular ligands that can postulated that cytokines, signalling via their cognate stimulate biological responses in diverse cell types by receptors, may play an instructive role in lineage binding to, and activating, a family of structurally and specification in hematopoiesis. An alternative to this functionally conserved cytokine receptors. instructive hypothesis is the stochastic or permissive Cytokines of the hematopoietic system include inter- hypothesis. The latter proposes that commitment to a leukins (ILs), colony-stimulating factors (CSFs), inter- particular hematopoietic lineage is an event that occurs ferons, erythropoietin (EPO) and thrombopoietin independently of extrinsic signals. It predicts that the role (TPO). They bind to a family of cytokine receptors that of cytokines is to provide nonspecific survival and share a number of features. The receptors can be proliferation signals. In this review, we look at the role composed of dimers of a single receptor (granulocyte of cytokine receptor signalling in hematopoiesis and (G)-CSF receptor (R), EPO receptor (EPOR), TPO consider the evidence for both hypotheses.
    [Show full text]
  • Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma
    ell Res C ea m rc te h S & f o T h l Journal of e a Ria and Vacca, J Stem Cell Res Ther 2014, 4:8 r n a r p u DOI: 10.4172/2157-7633.1000226 y o J ISSN: 2157-7633 Stem Cell Research & Therapy Review Article Open Access Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma Roberto Ria* and Angelo Vacca Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy Abstract Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients with newly diagnosed symptomatic multiple myeloma (MM). The introduction into clinical practice of novel agents (i.e.: proteasome inhibitors and immunomodulatory derivatives [IMiDs]) has significantly contributed to major advances in MM therapy and prognosis. These novel agents are incorporated into induction regimens to enhance the depth of response before ASCT and further improve post-ASCT outcomes. Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful autologous transplantation. The mobilizing regimen usually consists of cyclophosphamide or disease-specific agents, in combination with a hematopoietic cytokine, usually G-CSF, which mobilizes HPSCs into the bloodstream, in particular when administered after myelosuppressive chemotherapy. In some patients, the number of mobilized CD34+ cells is not sufficient to perform successful stem cell transplantation due to bone marrow damage by neoplastic proliferation and/or chemoradiotherapy. To improve the collection of CD34+ cells, the mobilization procedure can be repeated or an alternative chemotherapy regimen can be chosen. Recently, the new drug plerixafor (Mozobil®) has been introduced to increase the number of circulating CD34+ cells.
    [Show full text]
  • Kit Transduced Signals Counteract Erythroid Maturation by MAPK-Dependent Modulation of Erythropoietin Signaling and Apoptosis Induction in Mouse Fetal Liver
    Cell Death and Differentiation (2015) 22, 790–800 & 2015 Macmillan Publishers Limited All rights reserved 1350-9047/15 www.nature.com/cdd Kit transduced signals counteract erythroid maturation by MAPK-dependent modulation of erythropoietin signaling and apoptosis induction in mouse fetal liver N Haas1, T Riedt2, Z Labbaf1, K Baßler1, D Gergis3, H Fröhlich3, I Gütgemann1, V Janzen2 and H Schorle*,1 Signaling by the stem cell factor receptor Kit in hematopoietic stem and progenitor cells is functionally associated with the regulation of cellular proliferation, differentiation and survival. Expression of the receptor is downregulated upon terminal differentiation in most lineages, including red blood cell terminal maturation, suggesting that omission of Kit transduced signals is a prerequisite for the differentiation process to occur. However, the molecular mechanisms by which Kit signaling preserves the undifferentiated state of progenitor cells are not yet characterized in detail. In this study, we generated a mouse model for inducible expression of a Kit receptor carrying an activating mutation and studied its effects on fetal liver hematopoiesis. We found that sustained Kit signaling leads to expansion of erythroid precursors and interferes with terminal maturation beyond the erythroblast stage. Primary KITD816V erythroblasts stimulated to differentiate fail to exit cell cycle and show elevated rates of apoptosis because of insufficient induction of survival factors. They further retain expression of progenitor cell associated factors c-Myc, c-Myb and GATA-2 and inefficiently upregulate erythroid transcription factors GATA-1, Klf1 and Tal1. In KITD816V erythroblasts we found constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, elevated expression of the src kinase family member Lyn and impaired Akt activation in response to erythropoietin.
    [Show full text]
  • Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantat
    CLINICAL RESEARCH Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies Dawn Sheppard, Christopher Bredeson, David Allan, Jason Tay Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful autologous transplanta- tion; however, a proportion of patients fail to collect the minimum number of cells required. We summarized the efficacy and safety of HSC mobilization strategies. We performed a systematic review of randomized controlled trials comparing HSC mobilization strategies before autologous transplantation for hematologic malignancies. The primary outcome was CD341 cell yield. Secondary outcomes included number of apher- eses, proportion of failures, rate of count recovery, and adverse events. We identified 28 articles within 3 broad strategies. Using a cyclophosphamide with growth factor strategy (10 articles), CD341 cell yield is improved by addition of molgramostim to cyclophosphamide (1.4 vs 0.5 Â 106/kg; P 5 .0165), addition of cyclophosphamide to filgrastim (7.2 vs 2.5 Â 106/kg; P 5.004), and addition of ancestim to cyclophosphamide and filgrastim (12.4 vs 8.3 Â 106/kg; P 5.007). Within a growth factor-based strategy (6 articles), addition of plerixafor improves CD341 cell yield over filgrastim alone in multiple myeloma (MM; 11.0 vs 6.2 Â 106/kg; P \ .001) and non-Hodgkin lymphoma (5.69 vs 1.98 Â 106/kg; P \ .01). With combination or noncyclophosphamide-based chemotherapy (12 articles), higher-dose filgrastim (8.2 vs 4.7 Â 106/kg for 16 vs 8/mcg/kg daily of filgrastim, respectively; P \.0001) and addition of rituximab to etoposide and filgras- tim (9.9 vs 5.6 Â 106/kg; P 5.021) improve CD341 cell yield.
    [Show full text]
  • Method of Production of Transgenic Avian Using Embryonic Stem Cells
    (19) TZZ ZZ__T (11) EP 2 500 417 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.09.2012 Bulletin 2012/38 C12N 5/0735 (2010.01) A01K 67/027 (2006.01) (21) Application number: 12167371.9 (22) Date of filing: 09.08.2007 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Valarche, Isabelle HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE 44000 Nantes (FR) SI SK TR • Batard, Luc Designated Extension States: 44000 Nantes (FR) AL BA HR MK RS • Mehtali, Majid 44220 Coueron (FR) (30) Priority: 09.08.2006 US 836378 P (74) Representative: Flesselles, Bruno F.G. et al (62) Document number(s) of the earlier application(s) in BF IP accordance with Art. 76 EPC: 4, rue Ribera 07802553.3 / 2 054 507 75016 Paris (FR) (71) Applicant: Vivalis Remarks: 49450 Roussay (FR) This application was filed on 09-05-2012 as a divisional application to the application mentioned under INID code 62. (54) Method of production of transgenic avian using embryonic stem cells (57) The present invention concerns a method of cul- inhibitory factor (LIF), interleukin 11 (II-11), oncostatin turing embryonic stem (ES) cells of avian, comprising the and cardiotrophin; b) seeding the suspension of ES cells steps of: a) suspending ES cells originating from the blas- obtained in step a) on a layer of feeder cells and further toderm disk of fertilized un-incubated avian egg(s) in a culturing the ES cells for at least between 2 to 10 pas- basal culture medium supplemented with: insulin-like sages; c) optionally removing at least one growth factors growth factor-1 (IGF-1) and ciliary neurotrophic factor selected SCF, FGF, II-6, II-6R, LIF, oncostatin and car- (CNTF); and animal serum; and optionally, at least one diotrophin and II-11 from the culture medium; d) further growth factors selected in the group comprising inter- culturing the ES cells in the medium of step c) on a layer leukin 6 (II-6), interleukin 6 receptor (II-6R), stem cell of feeder cells.
    [Show full text]
  • Human Granulocyte-Colony Stimulating Factor (G-CSF)/Stem Cell Factor (SCF) Fusion Proteins: Design, Characterization and Activity
    Human granulocyte-colony stimulating factor (G-CSF)/stem cell factor (SCF) fusion proteins: design, characterization and activity Gitana Mickiene1,2, Indrė Dalgėdienė1, Gintautas Zvirblis1, Zilvinas Dapkunas1,2, Ieva Plikusiene3, Ernesta Buzavaite-Verteliene4, Zigmas Balevičius4, Audronė Rukšėnaitė1 and Milda Pleckaityte1 1 Institute of Biotechnology, Vilnius University, Vilnius, Lithuania 2 Profarma UAB, Vilnius, Lithuania 3 Department of Physical Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Vilnius, Lithuania 4 Plasmonics and Nanophotonics Laboratory, Department of Laser Technology, Center for Physical Sciences and Technology, Vilnius, Lithuania ABSTRACT Background: Stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) are well-characterized vital hematopoietic growth factors that regulate hematopoiesis. G-CSF and SCF synergistically exhibit a stimulatory effect on hematopoietic progenitors. The combination of G-CSF and SCF has been used for mobilization of peripheral blood progenitor cells in cancer and non-cancerous conditions. To overcome challenges connected with the administration of two cytokines, we developed two fusion proteins composed of human SCF and human G-CSF interspaced by an alpha-helix-forming peptide linker. Methods: The recombinant proteins SCF-La-GCSF and GCSF-La-SCF were purified in three steps using an ion-exchange and mixed-mode chromatography. The purity and quantity of the proteins after each stage of purification was assessed using RP-HPLC, SDS-PAGE, and the Bradford assays. Purified proteins were Submitted 22 April 2020 identified using high-performance liquid chromatography/electrospray ionization Accepted 31 July 2020 mass spectrometry (HPLC/ESI-MS) and the Western blot analyses. The molecular Published 21 August 2020 weight was determined by size exclusion HPLC (SE-HPLC).
    [Show full text]